These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36484163)

  • 1. Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia.
    Sorcini D; De Falco F; Gargaro M; Bozza S; Guarente V; Cardinali V; Stella A; Adamo FM; Silva Barcelos EC; Rompietti C; Dorillo E; Geraci C; Esposito A; Arcaleni R; Capoccia S; Mameli MG; Graziani A; Moretti L; Cipiciani A; Riccardi C; Mencacci A; Fallarino F; Rosati E; Sportoletti P
    Br J Haematol; 2023 Apr; 201(1):45-57. PubMed ID: 36484163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
    Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
    Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
    J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab.
    Bacova B; Kohutova Z; Zubata I; Gaherova L; Kucera P; Heizer T; Mikesova M; Karel T; Novak J
    Clin Exp Med; 2023 Jun; 23(2):371-379. PubMed ID: 35352210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.
    Barber VS; Peckham N; Duley L; Francis A; Abhishek A; Moss P; Cook JA; Parry HM
    BMJ Open; 2023 Sep; 13(9):e077946. PubMed ID: 37770269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
    Campanella A; Capasso A; Heltai S; Taccetti C; Albi E; Herishanu Y; Haggenburg S; Chatzikonstantinou T; Doubek M; Kättström M; Giannopoulos K; Simkovic M; Moreno C; Massaia M; Bumbea H; Alshemmari S; Ranghetti P; Perotta E; Martini F; Sant'Antonio E; Colia M; Combi C; Levi S; Kater AP; Hazenberg M; Nijhof IS; Hofsink Q; Demosthenous C; Kotaskova J; Zaleska J; Vrbacky F; Raya AM; Bisogno D; Tripoli IE; Popov VM; Roman V; Stavroyianni N; Karypidou M; Scarano E; Locatelli M; Frenquelli M; Scarfò L; Stamatopoulos K; Ghia P
    Am J Hematol; 2024 Apr; 99(4):745-750. PubMed ID: 38264829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L; Poh C; Sorensen T; Gopal AK; Warren EH; Till BG; Lee S; Gausman D; Smith SD; Gooley T; Greninger A
    Br J Haematol; 2022 May; 197(3):306-309. PubMed ID: 35149986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
    Haydu JE; Maron JS; Redd RA; Gallagher KME; Fischinger S; Barnes JA; Hochberg EP; Johnson PC; Takvorian RW; Katsis K; Portman D; Ruiters J; Sechio S; Devlin M; Regan C; Blumenthal KG; Banerji A; Judd AD; Scorsune KJ; McGree BM; Sherburne MM; Lynch JM; Weitzman JI; Lei M; Kotton CN; Dighe AS; Maus MV; Alter G; Abramson JS; Soumerai JD
    Blood Adv; 2022 Mar; 6(6):1671-1683. PubMed ID: 35073571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
    Doukas PG; St Pierre F; Karmali R; Mi X; Boyer J; Nieves M; Ison MG; Winter JN; Gordon LI; Ma S
    Oncologist; 2023 Oct; 28(10):e930-e941. PubMed ID: 37141401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.
    Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
    Blood Adv; 2023 May; 7(10):2214-2227. PubMed ID: 36630562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion.
    Shen Y; Freeman JA; Holland J; Naidu K; Solterbeck A; Van Bilsen N; Downe P; Kerridge I; Wallman L; Akerman A; Aggarwal A; Milogiannakis V; Martins Costa Gomes G; Doyle CM; Sandgren KJ; Turville S; Cunningham AL; Mulligan SP
    Blood; 2022 Dec; 140(25):2709-2721. PubMed ID: 36206503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
    Molica S; Tam C; Polliack A
    Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.
    Zaleska J; Kwasnik P; Paziewska M; Purkot J; Szabelak A; Jurek M; Masny N; Dziatkiewicz I; Pronobis-Szczylik B; Piebiak A; Szymczyk A; Jarosz-Chudzik K; Bolkun L; Kozlowska K; Piszcz J; Subocz E; Halka J; Bator M; Kalicinska E; Wrobel T; Usnarska-Zubkiewicz L; Rybka J; Deren-Wagemann I; Szyca-Smieszniak M; Dybko J; Hus I; Pula B; Cichocka E; Rymko M; Zdunczyk D; Ziarkiewicz M; Basak GW; Bullinger L; Giannopoulos K
    Int J Cancer; 2023 Feb; 152(4):705-712. PubMed ID: 35830214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
    Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
    Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses.
    Rydyznski Moderbacher C; Kim C; Mateus J; Plested J; Zhu M; Cloney-Clark S; Weiskopf D; Sette A; Fries L; Glenn G; Crotty S
    J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 35943810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.